| Date | Form | Description | Docs | XBRL | Pages |
| 01/17/14 | 10-K/A | Annual report pursuant to section 13 and 15(d) |
|
|
6 |
| 01/16/14 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
111 | |
| 08/27/13 | ARS | Annual report to security holders |
|
108 | |
| 01/29/13 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
|
244 |
| 01/30/12 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
|
94 |
| 02/14/11 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
102 | |
| 01/31/11 | NT 10-K | Notice under Rule 12b25 of inability to timely file all or part of a Form 10-K, 10-KSB, or 10KT |
|
4 | |
| 06/29/10 | 10-K/A | Annual report pursuant to section 13 and 15(d) |
|
81 | |
| 03/10/10 | 10-K/A | Annual report pursuant to section 13 and 15(d) |
|
80 | |
| 01/29/10 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
121 |
Latest News & Events
Anixa Biosciences and OntoChem Have Synthesized Four Potential Covid-19 Drugs for Testing in Biological Assays
Read More...Anixa Biosciences and OntoChem Announce Discovery of First Covid-19 Therapeutic Candidate
Read More...Anixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Biomarker Insights Highlighting Cchek™ Liquid Biopsy Technology
Read More...